Peter Lawson
Stock Analyst at Barclays
(1.34)
# 3,393
Out of 4,761 analysts
95
Total ratings
36%
Success rate
-10.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Equal-Weight | $25 → $29 | $36.85 | -21.30% | 5 | Feb 13, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $48 → $32 | $17.77 | +80.08% | 7 | Feb 3, 2025 | |
| BMEA Biomea Fusion | Maintains: Equal-Weight | $9 → $11 | $3.46 | +217.92% | 4 | Oct 30, 2024 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $25 → $29 | $11.07 | +161.97% | 6 | Oct 25, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $54 → $60 | $41.34 | +45.14% | 3 | Sep 27, 2024 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $14 → $17 | $3.92 | +333.67% | 5 | Sep 10, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $32 → $33 | $16.38 | +101.47% | 4 | Aug 15, 2024 | |
| IMCR Immunocore Holdings | Maintains: Overweight | $92 → $66 | $29.92 | +120.59% | 2 | Aug 9, 2024 | |
| MGNX MacroGenics | Maintains: Overweight | $9 → $8 | $2.76 | +189.86% | 8 | Jul 31, 2024 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $75 → $105 | $92.25 | +13.82% | 10 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $16.87 | +83.76% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $13.98 | +21.60% | 3 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $2.36 | +450.85% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $2.17 | +314.75% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $22 | $5.78 | +280.62% | 5 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $63 | $58.25 | +8.15% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $10 | $1.42 | +604.23% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $2 → $1 | $0.56 | +78.73% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.87 | +474.12% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $8 | $0.60 | +1,236.90% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $11.66 | +157.29% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $0.78 | +348.72% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $94.20 | +287.47% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $35.22 | +30.61% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $28 | $15.74 | +77.89% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.93 | +3,118.19% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $1.92 | +2,243.75% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $47.91 | -6.07% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.04 | +6,630.77% | 1 | Jul 14, 2017 |
Exelixis
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $25 → $29
Current: $36.85
Upside: -21.30%
Arvinas
Feb 3, 2025
Maintains: Overweight
Price Target: $48 → $32
Current: $17.77
Upside: +80.08%
Biomea Fusion
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $9 → $11
Current: $3.46
Upside: +217.92%
Arcus Biosciences
Oct 25, 2024
Maintains: Overweight
Price Target: $25 → $29
Current: $11.07
Upside: +161.97%
Revolution Medicines
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $41.34
Upside: +45.14%
Relay Therapeutics
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $3.92
Upside: +333.67%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $16.38
Upside: +101.47%
Immunocore Holdings
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $29.92
Upside: +120.59%
MacroGenics
Jul 31, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $2.76
Upside: +189.86%
Blueprint Medicines
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $75 → $105
Current: $92.25
Upside: +13.82%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $16.87
Upside: +83.76%
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $13.98
Upside: +21.60%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $2.36
Upside: +450.85%
Mar 7, 2024
Maintains: Overweight
Price Target: $7 → $9
Current: $2.17
Upside: +314.75%
Feb 29, 2024
Maintains: Overweight
Price Target: $18 → $22
Current: $5.78
Upside: +280.62%
Feb 29, 2024
Maintains: Overweight
Price Target: $47 → $63
Current: $58.25
Upside: +8.15%
Feb 27, 2024
Maintains: Overweight
Price Target: $6 → $10
Current: $1.42
Upside: +604.23%
Aug 10, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $0.56
Upside: +78.73%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.87
Upside: +474.12%
Aug 5, 2022
Maintains: Overweight
Price Target: $14 → $8
Current: $0.60
Upside: +1,236.90%
Jul 28, 2022
Initiates: Overweight
Price Target: $30
Current: $11.66
Upside: +157.29%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $0.78
Upside: +348.72%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $94.20
Upside: +287.47%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $35.22
Upside: +30.61%
Mar 4, 2020
Initiates: Underweight
Price Target: $28
Current: $15.74
Upside: +77.89%
Mar 4, 2020
Initiates: Overweight
Price Target: $30
Current: $0.93
Upside: +3,118.19%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $1.92
Upside: +2,243.75%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $47.91
Upside: -6.07%
Jul 14, 2017
Initiates: Buy
Price Target: $70
Current: $1.04
Upside: +6,630.77%